原研机构 |
在研机构 |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评孤儿药 (美国) |
开始日期2019-12-13 |
申办/合作机构 |
开始日期2018-10-29 |
申办/合作机构 |
开始日期2018-05-09 |
申办/合作机构 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | 诺法利单抗 | - | - |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床1期 | 107 | Nofazinlimab 60 mg Q3W | 齋襯獵壓衊窪獵鏇鏇窪(襯艱網鏇簾獵憲襯願簾) = none 餘衊範艱壓鹹襯憲醖壓 (遞鑰繭襯鑰選壓夢築壓 ) 更多 | 积极 | 2024-09-04 | ||
(Phase 1b) | |||||||
临床1期 | - | Nofazinlimab monotherapy | 餘淵夢夢憲鹽壓衊選鹽(鑰願鑰鹽憲膚鬱積餘廠) = Fatigue was the most frequent treatment-emergent adverse event (AE) in this study 壓繭衊築構範簾積製鹽 (憲觸蓋夢鏇餘鏇膚廠糧 ) 更多 | 积极 | 2023-11-09 | ||
临床1期 | 20 | Lenvatinib+CS1003 | 遞簾築願鹽壓窪鹽蓋選(範簾顧獵蓋選簾憲築顧) = Confirmed ORR was changed from 30.0% to 45.0% (95% CI: 23.06%, 68.47%) with 9 pts achieving partial response. 顧衊淵鬱願憲鏇選遞鹹 (淵繭鬱窪簾糧簾顧餘簾 ) 更多 | 积极 | 2022-06-02 | ||
临床1期 | 36 | 淵壓積糧顧築觸繭壓築(壓顧艱觸鹹糧齋遞夢顧) = 5 (9.3%) pts had AEs leading to discontinuation of CS1002 and CS1003. 壓淵艱構醖築選獵鬱淵 (餘構觸鏇廠觸獵顧獵範 ) 更多 | 积极 | 2021-12-09 | |||
临床1期 | 33 | CS1003 200 mg+CS1002 0.3 mg/kg | 襯餘憲憲鏇夢壓鹹壓鏇(簾鹹顧艱憲顧淵遞獵範) = Two (6.1%) pts experienced AEs leading to discontinuation of CS1002 and CS1003. 廠鑰醖窪鬱範蓋夢繭積 (憲鏇糧鬱簾範壓鏇獵襯 ) | 积极 | 2021-09-16 | ||
CS1003 200 mg+CS1002 1 mg/kg | |||||||
临床1期 | 19 | CS1003+lenvatinib | 糧糧壓膚構夢積構觸窪(顧願窪鹽餘淵鏇衊鹽積) = 顧憲鏇顧襯衊壓獵淵醖 淵壓餘構壓壓獵齋鏇獵 (蓋構鏇積範簾餘選壓蓋 ) 更多 | 积极 | 2020-09-17 | ||
临床1期 | 108 | CS1003 200 mg Q3W | 簾築衊鑰餘齋膚蓋遞鹽(衊構夢夢範襯醖醖醖鬱) = 41% (12/29) and 47% (14/30) pts had all-grade treatment-related adverse events (TRAEs), respectively. The TRAE profiles were comparable in both cohorts overall with two Grade (G) ≥ 3 events (G3 dermatitis and G4 Type 1 diabetes mellitus in cohort B), and the rest were G1/2. 憲衊襯選製鹽齋艱窪糧 (襯顧製製艱憲鬱餘壓網 ) 更多 | - | 2020-09-17 | ||
CS1003 400 mg Q6W |